Plant Name: Garcinia multiflora
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.882E-13 | 1.830E-09 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, ESR2, MMP1, MMP2, MMP9, PTPN1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.695E-26 | 2.111E-21 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.659E-06 | 4.825E-03 | APEX1, POLB |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 2.952E-06 | 4.944E-03 | APEX1, CA2, CA9, DAPK1, LMNA, MCL1, MMP9, NFKB1, POLB, PTPN1, TDP1, TP53 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 7.968E-06 | 9.505E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.773E-20 | 5.642E-16 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.491E-18 | 1.085E-14 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.425E-25 | 4.558E-23 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.437E-09 | 2.800E-07 | MMP1; DAPK1; MMP2; MMP9; TP53 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.448E-05 | 1.184E-03 | MMP1; DAPK1; MMP2; TP53; MMP9; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 7.102E-05 | 1.829E-03 | LMNA; TP53; NFKB1; MCL1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 5.258E-04 | 1.083E-02 | MMP2; MMP9; ESR2 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.235E-03 | 1.868E-02 | TP53; MMP9; NFKB1; MCL1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.619E-03 | 2.084E-02 | TP53; MMP9; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 4.114E-03 | 3.960E-02 | MMP2; TP53; MMP9 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 4.229E-03 | 3.960E-02 | POLB; TP53; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.935E-03 | 3.359E-02 | TP53; MMP9; NFKB1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.270E-03 | 1.868E-02 | POLB; APEX1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.991E-03 | 4.284E-02 | TP53; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 5.912E-03 | 4.467E-02 | NFKB1; ESR2 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 6.072E-03 | 4.467E-02 | TP53; NFKB1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia | E79.0, M10 | SLC22A12 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; TP53; MMP9; MMP2 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; MMP9 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA9; TP53; CA1; MMP9; NFKB1; MMP2; MCL1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2 |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | SLC22A12 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |